SCHEMBL4866628

SCHEMBL4866628

O=C(N[C@@H]1COc2cccc(CN3CCCCC3)c2C1)c1ccc(N2CCCCC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.50
HTR2A P28223 8/20 0.50
DRD3 P35462 8/20 0.50
SCN9A Q15858 7/20 0.48
KCNH2 Q12809 5/20 0.48
SCN5A Q14524 5/20 0.47
SMYD3 Q9H7B4 2/20 0.46
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866636 1.00 DRD2 (0.50) DRD2HTR2ADRD3SCN9AKCNH2
SCHEMBL4750025 0.84 SCN9A (0.65) HTR2ADRD3SCN9AKCNH2SCN5A
SCHEMBL4750963 0.84 SCN9A (0.51) SCN9AKCNH2SCN5ANPC1RAB9A
SCHEMBL4750039 0.83 SCN9A (0.66) HTR2ADRD3SCN9AKCNH2SCN5A
SCHEMBL4747610 0.81 SCN9A (0.52) SCN9AKCNH2SCN5A
SCHEMBL4838400 0.81 KCNH2 (0.70) DRD2HTR2ADRD3SCN9AKCNH2
SCHEMBL4838380 0.81 KCNH2 (0.70) DRD2HTR2ADRD3SCN9AKCNH2
SCHEMBL4749784 0.78 SCN9A (0.41) DRD2HTR2ADRD3SCN9AKCNH2
SCHEMBL4750462 0.78 SCN9A (0.53) DRD2HTR2ADRD3SCN9AKCNH2
SCHEMBL4749667 0.77 SCN9A (0.42) DRD2HTR2ADRD3SCN9AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008130319-A2 NOVEL N-TETRAHYDRONAPHTALENE OR N-CHROMANE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2008-10-30 WO claimed
WO-2008130319-A2 NOVEL N-TETRAHYDRONAPHTALENE OR N-CHROMANE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2008-10-30 WO disclosed